Search

Displaying results 2431 - 2440 of 6951 in total
  1. Drug

    Ozenoxacin

    go.drugbank.com/drugs/DB12924
    Approved

    s Xepi (ozenoxacin 1%) as a topically applied cream indicated for the treatment of impetigo caused by *Staphylococccus aureus* or *Streptococcus pyogenes* in adult and pediatric patients 2 months of age

    Categories: Antibiotics for Topical Use
  2. Drug

    Deutetrabenazine

    go.drugbank.com/drugs/DB12161
    ApprovedInvestigational

    Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. … As with other agents for the treatment of neurodegenerative diseases, deutetrabenazine is a drug to alleviate the motor symptoms of HD and is not proposed to halt the progression of the disease [T28].

  3. Drug

    Huperzine A

    go.drugbank.com/drugs/DB04864
    ApprovedInvestigationalWithdrawn

    The botanical has been used in China for centuries for the treatment of swelling, fever and blood disorders. Recently in clinical trials in China, it has demonstrated neuroprotective effects. … It is currently being investigated as a possible treatment for diseases characterized by neurodegeneration – particularly Alzheimer’s disease.

  4. Drug

    Deuruxolitinib

    go.drugbank.com/drugs/DB18847
    ApprovedInvestigational

    [A264113] On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata.

  5. Drug

    Tebentafusp

    go.drugbank.com/drugs/DB15283
    ApprovedInvestigational

    [L39995] Tebentafusp was subsequently approved for the same indication in the EU in April 2022.[L41675] … [A244815] On January 26, 2022, tebentafusp was first approved by the FDA for the treatment of HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma.

  6. Drug

    Ramipril

    go.drugbank.com/drugs/DB00178
    ApprovedInvestigational

    Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).

    Categories: Antihypertensive Agents Indicated for Hypertension
  7. Drug

    Finerenone

    go.drugbank.com/drugs/DB16165
    ApprovedInvestigational

    [A236544] So far, finerenone is the only nonsteroidal mineralocorticoid receptor antagonist to be FDA approved. … [A236544] Spironolactone has low selectivity and affinity for the receptor; it dissociates quickly and can also have effects at the androgen, progesterone, and glucocorticoid receptors.

    Categories: Mineralocorticoid Receptor Antagonists, Nonsteroidal Mineralocorticoid-Receptor Antagonist
  8. Drug

    Setmelanotide

    go.drugbank.com/drugs/DB11700
    ApprovedInvestigational

    Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. … [L24474] It is an agonist of the melanocortin 4 receptor.

    Categories: Melanocortin 4 Receptor Agonist, Melanocortin 4 Receptor Agonists
  9. Drug

    Quazepam

    go.drugbank.com/drugs/DB01589
    ApprovedIllicit

    [L44913] It appears to be unique amongst other benzodiazepine derivatives in its relatively high affinity for sleep-promoting α1 subunit-containing GABA<sub>A</sub> receptors and low affinity for other … It was first approved in the US in 1985 and is used as a hypnotic for the treatment of insomnia.

  10. Drug

    Fluticasone

    go.drugbank.com/drugs/DB13867
    ApprovedInvestigationalWithdrawn

    These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358,F4361,F4364][FDA Label].

    Categories: Corticosteroids for inhalation use, Drugs for Obstructive Airway Diseases